Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a needle-free delivery system for Xeomin (botulinum toxin A) aimed at treating overactive bladder in a minimally invasive manner. Vensica was established in the incubator program of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/28/24 | $11,000,000 |
Israel Biotech Fund Laborie Medical Technologies Merz | undisclosed |
